Quantum Genomics reports total capital increase after stabilization period: €12.9 million

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces that broking firm Invest Securities, as Lead Manager and Bookrunner, has informed the Company that the overallotment option, granted to it as part of the capital increase with public offering on the Euronext Alternext market in Paris, was exercised in full in the amount of an additional €1.7 million corresponding to the issue of 267,375 additional shares at the offer price of €6.30 per share.

Download press release